EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites

Oliver Looker, Madeline G Dans, Hayley E Bullen, Brad E Sleebs, Brendan S Crabb, Paul R Gilson

Traffic · 2022-09 · 23 (9) · 442-461

DOI: 10.1111/tra.12862 ↗

At a glance

Journal article in Traffic, published online on 2022-08-15. Written by Oliver Looker and 5 co-authors. Institution: Burnet Institute, Melbourne, Australia. Major MEDLINE topics: Antimalarials, Malaria, Malaria, Falciparum, Parasites. Cited 15 times so far (Crossref); 102 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Health and Medical Research Council.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Plasmodium falciparum parasites which cause malaria, traffic hundreds of proteins into the red blood cells (RBCs) they infect. These exported proteins remodel their RBCs enabling host immune evasion through processes such as cytoadherence that greatly assist parasite survival. As resistance to all current antimalarial compounds is rising new compounds need to be identified and those that could inhibit parasite protein secretion and export would both rapidly reduce parasite virulence and ultimately lead to parasite death. To identify compounds that inhibit protein export we used transgenic parasites expressing an exported nanoluciferase reporter to screen the Medicines for Malaria Venture Malaria Box of 400 antimalarial compounds with mostly unknown targets. The most potent inhibitor identified in this screen was MMV396797 whose application led to export inhibition of both the reporter and endogenous exported proteins. MMV396797 mediated blockage of protein export and slowed the rigidification and cytoadherence of infected RBCs—modifications which are both mediated by parasite‐derived exported proteins. Overall, we have identified a new protein export inhibitor in P. falciparum whose target though unknown, could be developed into a future antimalarial that rapidly inhibits parasite virulence before eliminating parasites from the host.

Subjects

MeSH terms (MEDLINE)

AntimalarialsMalariaMalaria, FalciparumParasitesAnimalsErythrocytesHumansPlasmodium falciparumProtozoan Proteins

Author keywords

Plasmodium falciparumantimalarialsmalariaprotein transportsmall molecule libraries

Substances

AntimalarialsProtozoan Proteins

Authors and institutions

  • Burnet Institute, Melbourne, Australia.
  • School of Medicine, Deakin University, Geelong, Australia.
  • Department of Immunology and Microbiology, University of Melbourne, Melbourne, Australia.
  • The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
  • Department of Medical Biology, The University of Melbourne, Parkville, Australia.
  • Department of Immunology and Pathology, Monash University, Melbourne, Australia.

Funding

  • National Health and Medical Research Council

Cite

APA

Looker, O., Dans, M. G., Bullen, H. E., Sleebs, B. E., Crabb, B. S., & Gilson, P. R. (2022). The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites. Traffic, 23(9), 442-461. https://doi.org/10.1111/tra.12862

Vancouver

Looker O, Dans MG, Bullen HE, Sleebs BE, Crabb BS, Gilson PR. The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites. Traffic. 2022;23(9):442-461. doi:10.1111/tra.12862

BibTeX
@article{Looker2022,
  author = {Looker, Oliver and Dans, Madeline G and Bullen, Hayley E and Sleebs, Brad E and Crabb, Brendan S and Gilson, Paul R},
  title = {The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites},
  journal = {Traffic},
  year = {2022},
  volume = {23},
  number = {9},
  pages = {442--461},
  doi = {10.1111/tra.12862}
}
Start for free →